TScan Therapeutics, Inc. Shares Bought by Brown Brothers Harriman Co.
| TCRX Stock | USD 4.77 0.13 2.80% |
Slightly above 66 percent of all Tscan Therapeutics' investors are curious in acquiring. The analysis of the overall investor sentiment regarding Tscan Therapeutics suggests that a large number of traders are confidant. Tscan Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Tscan Therapeutics' earnings reports, geopolitical events, and overall market trends.
Tscan |
Brown Brothers Harriman Co. raised its position in TScan Therapeutics, Inc. by 88.2 percent in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 143,051 shares of the companys stock after buying an additional 67,027 shares during the period. Brown Brothers Harriman
Read at thelincolnianonline.com
 |
Tscan Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Tscan Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Tscan Therapeutics Fundamental Analysis
We analyze Tscan Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tscan Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tscan Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Shares Shorted
Number Of Shares Shorted Comparative Analysis
Tscan Therapeutics is currently under evaluation in number of shares shorted category among its peers. Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Tscan Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Tscan Therapeutics stock to make a market-neutral strategy. Peer analysis of Tscan Therapeutics could also be used in its relative valuation, which is a method of valuing Tscan Therapeutics by comparing valuation metrics with similar companies.
Peers
Tscan Therapeutics Related Equities
| TFFP | Tff Pharmaceuticals | 9.68 | ||||
| ELYM | Eliem Therapeutics | 1.30 | ||||
| INBX | Inhibrx | 2.37 | ||||
| ELVN | Enliven Therapeutics | 4.05 |
Additional Tools for Tscan Stock Analysis
When running Tscan Therapeutics' price analysis, check to measure Tscan Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tscan Therapeutics is operating at the current time. Most of Tscan Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tscan Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tscan Therapeutics' price. Additionally, you may evaluate how the addition of Tscan Therapeutics to your portfolios can decrease your overall portfolio volatility.